Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications

John R. Richards, M.D. (Editor)
Department of Emergency Medicine, University of California, Davis School of Medicine, Sacramento, California, USA

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000

Clear

$230.00

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

In the late 1950s, Sir James Black made a tremendous contribution to pharmacology and medicine with his discovery of β-blockers. After the first β-blockers became available in the 1960s, these drugs were noted to have beneficial effects in reducing morbidity and mortality from ischemic heart disease. It soon thereafter became apparent that blocking the adverse effects of the sympathetic nervous system could benefit many other diseases. As research and development continued, later generations of β-blockers appeared, each with unique properties such that it is now impossible to group these agents into one class to uniformly describe their effects. In this edition of Beta-Blockers: Physiological, Pharmacological and Therapeutic Implications, the authors examine how β-blockers have evolved from their origin as a treatment for angina to a myriad of other related and unrelated medical conditions. These include (in order of appearance), heart failure, hypertension, sepsis, tachydysrhythmias, portal hypertension, variceal bleeding, stimulant toxicity, thyrotoxicosis, obstructive lung disease, trauma, pheochromocytoma, cancer, acute coronary syndromes, and coronary arterial disease. The authors of these chapters hail from a spectrum of medical specialties as diverse as the indications for β-blockers: anesthesiology, cardiology, critical care, emergency medicine, gastroenterology, hematology/oncology, internal medicine, pharmacology, pulmonology, surgery, and toxicology. In this book, we also discuss controversies as well as the evolving and changing indications and contraindications for the use of this amazing class of drugs. This book will be of interest to physicians, pharmacists, nurse practitioners, physician assistants, nurses, research scientists, and informed patients.

Preface

Chapter 1. Beta-Blockers for Heart Failure: Pharmacology, Relevance, and Justification
(Shahid Akbar and John R. Richards, Medical University of the Americas, Nevis, West Indies, and others)

Chapter 2. Beta-Blockers for Control of Hypertension: Controversy, Evidence, and Current Practice
(Shahid Akbar and John R. Richards, Medical University of the Americas, Nevis, West Indies, and others)

Chapter 3. Beta-Blockers in Critical Care and Obstructive Lung Diseases: New Directions
(Brooks T. Kuhn, E. Pierce Stewart, Mark V. Avdalovic, Timothy E. Albertson, and Michael Schivo, Department of Internal Medicine, University of California, Davis, Medical Center, Sacramento, California, and others)

Chapter 4. Beta-Blockers Following Traumatic Injury
(Tyler J. Loftus, Elizabeth S. Miller, and Alicia M. Mohr, Department of Surgery and Sepsis and Critical Illness Research Center, University of Florida, Gainesville, Florida, USA)

Chapter 5. Beta-Blocker Overdose: Progressive Treatment Options
(Timothy. E. Albertson, Alyrene A. Dorey, John R. Richards, and Susan Murin, Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of California, Davis School of Medicine, Sacramento, California, USA, and others)

Chapter 6. Beta-Blockade in Septic Shock: A Paradigm Shift in Management?
(Richard Browne and Tony Whitehouse, Department of Critical Care and Anaesthesia, Queen Elizabeth Hospital, Birmingham, United Kingdom)

Chapter 7. The Unopposed Alpha-Stimulation Phenomenon: What is the Role of Beta-Blockers?
(John R. Richards, Howard E. McKinney Jr, and Bernard Silke, Department of Emergency Medicine, University of California, Davis School of Medicine, Sacramento, California, USA, and others)

Chapter 8. Beta-Blockers and Cancer: An Emerging Treatment
(Shahid Akbar and John R. Richards, Medical University of the Americas, Nevis, West Indies, and others)

Chapter 9. The Use of Beta-Blockers in the Emergency Department
(Max Hockstein and Deborah Diercks, Department of Emergency Medicine, University of Texas Southwestern, Dallas, Texas, USA)

Chapter 10. Beta-Adrenergic Blockade in Patients with Myocardial Infarction: Evolution, Efficacy and Controversy
(Ezra A. Amsterdam, Shahad Al Chalaby, Sean Fraser, Naveen Gupta, Tina Gupta, Muhammad Majid, Balasingam Thevakumar, Navya Sree Vipparla, and Sandhya Venugopal, Division of Cardiovascular Medicine, Department of Internal Medicine, University of California, Davis School of Medicine, Sacramento, California, USA)

Chapter 11. Beta-Blocker Therapy for Acute Coronary Syndrome and Stable Coronary Artery Disease: Current Issues and Outcomes
(Manoj Kesarwani, Division of Cardiovascular Medicine, Department of Internal Medicine, University of California, Davis School of Medicine, Sacramento, California, USA, and others)

Index

You have not viewed any product yet.